Table 3.

Comparison of persistence and adherence

Outcomes	Mean differencea (95% CI), FTD + TPI vs. REG	p value	Odds ratiob (95% CI), FTD + TPI vs. REG	p value	Hazard ratioc (95% CI), FTD + TPI vs. REG	p value
MPR
MPR (%)	6.33 (4.03–8.64)	<.001d
MPR ≥80%			2.47 (1.60–3.79)	<.001d
PDC
PDC (%), at 3 mo	11.88 (8.17–15.59)	<.001d
PDC (%), at 6 mo	6.73 (0.22–13.23)	.043d
PDC ≥80%, at 3 mo			2.77 (1.95–3.94)	<.001d
PDC ≥80%, at 6 mo			1.43 (0.68–3.02)	.351
Time to discontinuation
No gap ≥45 d					.76 (0.63–0.93)	.006d
No gap ≥60 d					.91 (0.73–1.12)	.374

^aMean differences were estimated using multivariate linear models adjusted for demographic covariates (age, gender, region, insurance plan, year of index date), Quan‐Charlson comorbidity index, all‐cause baseline drug costs, all‐cause baseline medical costs.

^bOdds ratios were estimated using logit binomial models adjusted for demographic covariates (age, gender, region, insurance plan, year of index date), Quan‐Charlson comorbidity index, all‐cause baseline drug costs, all‐cause baseline medical costs.

^cHazard ratio were estimated using Cox proportional hazards models adjusted for demographic covariates (i.e., age, gender, region, insurance plan, year of index date), Quan‐Charlson comorbidity index, all‐cause baseline drug costs, all‐cause baseline medical costs.

^d p value < .05.

Abbreviations: CI, confidence interval; FTD + TPI, trifluridine + tipiracil; MPR, medication possession ratio; PDC, proportion of days covered; REG, regorafenib.